What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract.
作者信息
D'Alessio David A
机构信息
Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, ML 0547, University of Cincinnati, Cincinnati Ohio 45267-0547, USA.
出版信息
Endocrinology. 2011 Aug;152(8):2925-6. doi: 10.1210/en.2011-1385.
Abstract
摘要
相似文献
1
What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract.
Endocrinology. 2011 Aug;152(8):2925-6. doi: 10.1210/en.2011-1385.
2
Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.使用 DPP-4 抑制剂和 GLP-1 受体阻断剂来定义 GLP-1 在 2 型糖尿病肠促胰岛素轴中的作用。
Diabetes. 2014 Mar;63(3):1079-92. doi: 10.2337/db13-1455. Epub 2013 Dec 2.
3
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.通过二肽基肽酶-4 抑制剂西他列汀调控小鼠血糖的生理和药理机制。
Endocrinology. 2011 Aug;152(8):3018-29. doi: 10.1210/en.2011-0286. Epub 2011 Jun 14.
4
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.二肽基肽酶 4 抑制剂西他列汀通过胰高血糖素样肽 1 依赖机制保护高血压患者的血管内皮功能。
Hypertension. 2012 Sep;60(3):833-41. doi: 10.1161/HYPERTENSIONAHA.112.195115. Epub 2012 Aug 6.
5
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂的化学差异（结构）、作用机制及药理学
J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078.
6
The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.GLP-1 受体激动剂和 DPP-4 抑制剂之间临床差异的药理学基础。
Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508.
7
Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.天然、完整的胰高血糖素样肽 1 是生理流动条件下血栓生长的天然抑制剂。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):e65-e77. doi: 10.1161/ATVBAHA.119.313645. Epub 2020 Jan 2.
8
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.胰高血糖素样肽-1（GLP-1）受体激动或二肽基肽酶-4（DPP-4）抑制不会加速致癌物处理小鼠的肿瘤形成。
Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.
9
Incretins and Their Endocrine and Metabolic Functions.肠促胰岛素及其内分泌和代谢功能。
Endocr Dev. 2017;32:38-48. doi: 10.1159/000475730. Epub 2017 Aug 15.
10
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.肠促胰岛素系统：2型糖尿病中的胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂
Lancet. 2006 Nov 11;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5.
引用本文的文献
1
Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin.西他列汀对2型糖尿病患者蛋白尿的影响——西他列汀的肾脏保护作用。
J Res Med Sci. 2021 Jun 30;26:35. doi: 10.4103/jrms.JRMS_78_20. eCollection 2021.
2
Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells.番泻苷A通过激活L细胞中的ERK1/2信号通路诱导胰高血糖素样肽-1分泌。
Diabetes Metab Syndr Obes. 2020 Apr 29;13:1407-1415. doi: 10.2147/DMSO.S247251. eCollection 2020.
3
Neuropods.神经足。
Cell Mol Gastroenterol Hepatol. 2019;7(4):739-747. doi: 10.1016/j.jcmgh.2019.01.006. Epub 2019 Jan 30.
4
Microbial regulation of GLP-1 and L-cell biology.微生物对胰高血糖素样肽-1及L细胞生物学的调节
Mol Metab. 2016 May 28;5(9):753-8. doi: 10.1016/j.molmet.2016.05.012. eCollection 2016 Sep.
5
Synthetic small molecule GLP-1 secretagogues prepared by means of a three-component indole annulation strategy.通过三组分吲哚环化策略制备的合成小分子 GLP-1 分泌激动剂。
Sci Rep. 2016 Jun 29;6:28934. doi: 10.1038/srep28934.
6
The serine protease, dipeptidyl peptidase IV as a myokine: dietary protein and exercise mimetics as a stimulus for transcription and release.丝氨酸蛋白酶二肽基肽酶IV作为一种肌动蛋白：膳食蛋白质和运动模拟物作为转录和释放的刺激因素。
Physiol Rep. 2016 Jun;4(12). doi: 10.14814/phy2.12827.
7
Is GLP-1 a hormone: Whether and When?GLP-1 是激素吗：是否以及何时？
J Diabetes Investig. 2016 Apr;7 Suppl 1(Suppl 1):50-5. doi: 10.1111/jdi.12466. Epub 2016 Mar 14.
8
Gastrointestinal Endogenous Protein-Derived Bioactive Peptides: An in Vitro Study of Their Gut Modulatory Potential.胃肠道内源性蛋白质衍生的生物活性肽：对其肠道调节潜力的体外研究
Int J Mol Sci. 2016 Apr 1;17(4):482. doi: 10.3390/ijms17040482.
9
The L-Cell in Nutritional Sensing and the Regulation of Appetite.营养感应中的 L 细胞及其对食欲的调节作用。
Front Nutr. 2015 Jul 20;2:23. doi: 10.3389/fnut.2015.00023. eCollection 2015.
10
An Innate Disposition for a Healthier Gut: GLP-1R Signaling in Intestinal Epithelial Lymphocytes.肠道更健康的先天倾向：肠道上皮淋巴细胞中的胰高血糖素样肽-1受体信号传导
Diabetes. 2015 Jul;64(7):2329-31. doi: 10.2337/db15-0436.
本文引用的文献
1
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.通过二肽基肽酶-4 抑制剂西他列汀调控小鼠血糖的生理和药理机制。
Endocrinology. 2011 Aug;152(8):3018-29. doi: 10.1210/en.2011-0286. Epub 2011 Jun 14.
2
Genetic tracing of Nav1.8-expressing vagal afferents in the mouse.在小鼠中对表达 Nav1.8 的迷走传入神经进行遗传示踪。
J Comp Neurol. 2011 Oct 15;519(15):3085-101. doi: 10.1002/cne.22667.
3
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.西他列汀对空腹血糖受损患者肠促胰岛素分泌及空腹和餐后葡萄糖代谢的影响。
Clin Endocrinol (Oxf). 2010 Aug;73(2):189-96. doi: 10.1111/j.1365-2265.2009.03764.x. Epub 2009 Dec 18.
4
Incretin-based therapies for type 2 diabetes mellitus.用于2型糖尿病的基于肠促胰岛素的疗法。
Nat Rev Endocrinol. 2009 May;5(5):262-9. doi: 10.1038/nrendo.2009.48.
5
Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system.肠道淋巴液和门静脉血浆中胰高血糖素样肽-1（GLP-1）的空腹及餐后浓度：GLP-1在淋巴系统中选择性释放的证据
Am J Physiol Regul Integr Comp Physiol. 2007 Dec;293(6):R2163-9. doi: 10.1152/ajpregu.00911.2006. Epub 2007 Sep 26.
6
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.肠促胰岛素疗法治疗2型糖尿病的疗效与安全性：系统评价与荟萃分析
JAMA. 2007 Jul 11;298(2):194-206. doi: 10.1001/jama.298.2.194.
7
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.门静脉神经末梢上表达的胰高血糖素样肽-1（GLP-1）受体介导内源性GLP-1对大鼠葡萄糖耐量的影响。
Endocrinology. 2007 Oct;148(10):4965-73. doi: 10.1210/en.2006-0153. Epub 2007 Jun 21.
8
Biology of incretins: GLP-1 and GIP.肠促胰岛素的生物学：胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽
Gastroenterology. 2007 May;132(6):2131-57. doi: 10.1053/j.gastro.2007.03.054.
9
Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.门静脉葡萄糖与胰高血糖素样肽-1协同降低全身血糖并刺激反调节激素。
Diabetologia. 2005 May;48(5):967-75. doi: 10.1007/s00125-005-1709-3. Epub 2005 Apr 14.
10
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.胰高血糖素样肽-1介导二肽基肽酶-4抑制剂的治疗作用。
Diabetologia. 2005 Apr;48(4):612-5. doi: 10.1007/s00125-005-1705-7. Epub 2005 Mar 10.
Zotero 插件